Thyroid Gland Medullary Carcinoma — Trials

Thyroid Gland Medullary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

105 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 25
Recruiting: 8
Ph III recruiting: 1
Growth YoY: —
Industry share: 32%
Top sponsor: Eli Lilly and Company
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (11)

clinicaltrialsPublishedShowing 101–105 of 105 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00028496	Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	completed	Phase 1	48	National Cancer Institute (NCI)NIH	1	Jan 25, 2013	clinicaltrials
NCT01683110	Expanded Access of Cabozantinib in Medullary Thyroid Cancer	approved for marketing	—	—	ExelixisINDUSTRY	1	Jan 16, 2013	clinicaltrials